Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Net Cash Flow (2020 - 2025)

Treace Medical Concepts' Net Cash Flow history spans 6 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 497.63% year-over-year to $3.0 million; the TTM value through Dec 2025 reached -$642000.0, up 60.66%, while the annual FY2025 figure was -$642000.0, 60.66% up from the prior year.
  • Net Cash Flow reached $3.0 million in Q4 2025 per TMCI's latest filing, up from -$366000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $103.4 million in Q2 2021 to a low of -$69.1 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$368550.0, with a median of -$2.7 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 34783.56% in 2021, then crashed 1783.64% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$3.7 million in 2021, then plummeted by 1783.64% to -$69.1 million in 2022, then skyrocketed by 108.26% to $5.7 million in 2023, then plummeted by 113.32% to -$760000.0 in 2024, then soared by 497.63% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Net Cash Flow are $3.0 million (Q4 2025), -$366000.0 (Q3 2025), and -$5.3 million (Q2 2025).